Holen Sie sich die Stockscreener-App
1.24
0.80%
-0.01
Handel nachbörslich:
1.27
0.03
+2.42%
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
60,689
Relative Volume:
0.09
Marktkapitalisierung:
$2.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.85M
KGV:
-0.5368
EPS:
-2.31
Netto-Cashflow:
$-46.25M
1W Leistung:
-4.62%
1M Leistung:
-57.97%
6M Leistung:
-91.97%
1J Leistung:
-97.98%
1-Tages-Spanne:
$1.22
$1.285
1-Wochen-Bereich:
$1.22
$1.38
52-Wochen-Spanne:
$1.18
$187.44
Vincerx Pharma Inc Stock (VINC) Company Profile
Firmenname
Vincerx Pharma Inc
Sektor
Branche
Telefon
650-800-6676
Adresse
260 SHERIDAN AVENUE, PALO ALTO
Vergleichen Sie VINC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
1.24 | 2.78M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-01 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-13 | Eingeleitet | Laidlaw | Buy |
| 2021-08-25 | Eingeleitet | B. Riley Securities | Buy |
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Vincerx Pharma Regains Compliance With Nasdaq Listing Rule 5550(A)(2) -February 18, 2025 at 05:27 pm EST - Marketscreener.com
Vincerx Pharma announces reverse stock split; shares drop - MSN
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia
Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat
VINC stock touches 52-week low at $1.62 amid market challenges - Investing.com Canada
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma and Oqory reveal merger and cancer drug data - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Vincerx Pharma and Oqory reveal merger and cancer drug data By Investing.com - Investing.com UK
Revolutionary Cancer Treatment Achieves Unprecedented 80% Success Rate in Clinical Trial - StockTitan
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma enters at-the-market equity offering deal - MSN
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Vincerx Pharma (NASDAQ:VINC) Stock Quotes, Forecast and News Summary - Benzinga
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx Pharma files for $100M mixed securities shelf - MSN
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split - Defense World
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma (VINC) Stock Price, News & Analysis - MarketBeat
Vincerx Pharma Inc. Announces Merger with Oqory - TipRanks
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma Announces 1-for-20 Reverse Stock Split, Shares to Adjust January 28 - StockTitan
Vincerx Pharma enters at-the-market equity offering deal By Investing.com - Investing.com Australia
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
Vincerx Pharma ends sales agreement, approves reverse stock split By Investing.com - Investing.com Nigeria
VINC Stock Touches 52-Week Low at $0.17 Amid Market Challenges - Investing.com UK
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders - GlobeNewswire Inc.
Investor law firms question biotech merger's 'fairness' - The Business Journals
What Did We Find About Insider Trading At Vincerx Pharma Inc (NASDAQ: VINC)? - Stocks Register
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders - Stockhouse Publishing
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - Stockhouse Publishing
Vincerx Pharma Inc (NASDAQ: VINC): On Track To A Higher Share Price - Stocks Register
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, OMIC, NEUE, VINC on Behalf of Shareholders - GlobeNewswire
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders - Lelezard
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerVINC, VCSA, MRNS, MHLD - Markets Insider
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders - Business Wire
Stock market today: Intrusion surged by 123.33% while Snow Lake Resources plunged by 21.88% in early trading - Business Upturn
Finanzdaten der Vincerx Pharma Inc-Aktie (VINC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):